聚腺苷二磷酸核糖聚合酶抑制剂耐药机制在癌症中的研究进展及其对 DNA 损伤反应的启示
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.
机构信息
Institute of Animal Pathology, Vetsuisse Faculty, Länggassstrasse, University of Bern, 3012, Bern, Switzerland.
Division of Molecular Pathology, The Netherlands Cancer Institute, 1006 BE, Amsterdam, The Netherlands.
出版信息
Genome Med. 2018 Dec 28;10(1):101. doi: 10.1186/s13073-018-0612-8.
Abstract
Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle. Recent advances in the identification of PARPi resistance mechanisms have yielded a better understanding of DNA end protection and the relevance of endogenous poly(ADP-ribose) glycohydrolase, highlighting new vulnerabilities.
摘要
聚（ADP-核糖）聚合酶（PARPi）抑制剂已进入临床，用于治疗缺乏同源定向 DNA 修复的癌症患者，但耐药性仍然是临床面临的一个难题。最近在鉴定 PARPi 耐药机制方面的进展，使人们更好地理解了 DNA 末端保护和内源性聚（ADP-核糖）糖水解酶的相关性，突出了新的弱点。
相似文献
1
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.聚腺苷二磷酸核糖聚合酶抑制剂耐药机制在癌症中的研究进展及其对 DNA 损伤反应的启示
Genome Med. 2018 Dec 28;10(1):101. doi: 10.1186/s13073-018-0612-8.
2
DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.DNA损伤修复与聚（ADP-核糖）聚合酶抑制在癌症治疗中的新作用
Clin Ther. 2016 Jul;38(7):1577-88. doi: 10.1016/j.clinthera.2016.06.006. Epub 2016 Jun 29.
3
PARP inhibitor resistance: the underlying mechanisms and clinical implications.聚腺苷二磷酸核糖聚合酶抑制剂耐药性：潜在机制与临床意义。
Mol Cancer. 2020 Jun 20;19(1):107. doi: 10.1186/s12943-020-01227-0.
4
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.从多聚（ADP-核糖）聚合酶抑制到癌症治疗中的靶向 DNA 修复和 DNA 损伤反应。
J Clin Oncol. 2019 Sep 1;37(25):2257-2269. doi: 10.1200/JCO.18.02050. Epub 2019 May 3.
5
Reverse the Resistance to PARP Inhibitors.逆转对PARP抑制剂的耐药性。
Int J Biol Sci. 2017 Feb 17;13(2):198-208. doi: 10.7150/ijbs.17240. eCollection 2017.
6
Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.研究PAR依赖的染色质重塑以应对PARPi耐药性。
Trends Mol Med. 2021 Jul;27(7):630-642. doi: 10.1016/j.molmed.2021.04.010. Epub 2021 May 21.
7
PARPi focus the spotlight on replication fork protection in cancer.聚腺苷二磷酸核糖聚合酶（PARP）将焦点集中在癌症中的复制叉保护上。
Nat Cell Biol. 2017 Oct 31;19(11):1309-1310. doi: 10.1038/ncb3638.
8
Posttranscriptional Regulation of mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.HuR对mRNA的转录后调控促进DNA修复及对PARP抑制剂的抗性。
Cancer Res. 2017 Sep 15;77(18):5011-5025. doi: 10.1158/0008-5472.CAN-16-2704. Epub 2017 Jul 7.
9
A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.一种 I 型联合靶向方法，用于设计针对 BRCA1/2 突变体和表达 O6-甲基鸟嘌呤-DNA 甲基转移酶（mgmt）的肿瘤细胞具有增强效力的分子。
BMC Cancer. 2017 Aug 11;17(1):540. doi: 10.1186/s12885-017-3504-1.
10
Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.聚（ADP-核糖）聚合酶 1（PARP1）在癌症中的治疗靶点：当前的发展、治疗策略和未来的机会。
Med Res Rev. 2017 Nov;37(6):1461-1491. doi: 10.1002/med.21442. Epub 2017 May 16.
引用本文的文献
1
Current status, hotspots, and trends in cancer prevention, screening, diagnosis, treatment, and rehabilitation: A bibliometric analysis.癌症预防、筛查、诊断、治疗及康复的现状、热点与趋势：一项文献计量分析
Oncol Res. 2025 May 29;33(6):1437-1458. doi: 10.32604/or.2025.059290. eCollection 2025.
2
TAOK1 promotes filament formation in HR repair through phosphorylating USP7.TAOK1通过磷酸化USP7促进同源重组修复中的丝状结构形成。
Proc Natl Acad Sci U S A. 2025 Mar 25;122(12):e2422262122. doi: 10.1073/pnas.2422262122. Epub 2025 Mar 19.
3
A nanoscale natural drug delivery system for targeted drug delivery against ovarian cancer: action mechanism, application enlightenment and future potential.一种针对卵巢癌靶向药物递送的纳米级天然药物递送系统：作用机制、应用启示和未来潜力。
Front Immunol. 2024 Oct 11;15:1427573. doi: 10.3389/fimmu.2024.1427573. eCollection 2024.
4
Cold and hot tumors: from molecular mechanisms to targeted therapy.冷肿瘤和热肿瘤：从分子机制到靶向治疗。
Signal Transduct Target Ther. 2024 Oct 18;9(1):274. doi: 10.1038/s41392-024-01979-x.
5
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.PARP1 选择性抑制剂芦卡帕利（AZD5305）在源自患者的 BRCA1/2 相关癌症模型中引发了强大且持久的抗肿瘤活性。
Genome Med. 2024 Aug 26;16(1):107. doi: 10.1186/s13073-024-01370-z.
6
[F]F-Poly(ADP-Ribose) Polymerase Inhibitor Radiotracers for Imaging PARP Expression and Their Potential Clinical Applications in Oncology.[F]用于成像PARP表达的F-聚（ADP-核糖）聚合酶抑制剂放射性示踪剂及其在肿瘤学中的潜在临床应用
J Clin Med. 2024 Jun 11;13(12):3426. doi: 10.3390/jcm13123426.
7
Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives.乳腺癌中分子靶标和代谢途径的影像学研究：改善临床管理的现状和未来展望。
Int J Mol Sci. 2024 Jan 26;25(3):1575. doi: 10.3390/ijms25031575.
8
Aneuploid serves as a prognostic marker and favors immunosuppressive microenvironment in ovarian cancer.非整倍体可作为卵巢癌的预后标志物，并有利于免疫抑制微环境。
J Ovarian Res. 2024 Feb 2;17(1):30. doi: 10.1186/s13048-024-01356-w.
9
The Complex Network of ADP-Ribosylation and DNA Repair: Emerging Insights and Implications for Cancer Therapy.ADP-核糖基化与 DNA 修复的复杂网络：癌症治疗的新见解与启示。
Int J Mol Sci. 2023 Oct 9;24(19):15028. doi: 10.3390/ijms241915028.
10
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options.卵巢癌除了 PARP 抑制治疗以外：当前和未来的选择。
Drugs. 2023 Oct;83(15):1365-1385. doi: 10.1007/s40265-023-01934-0. Epub 2023 Sep 22.
本文引用的文献
1
The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.ASCIZ-DYNLL1 轴促进 53BP1 依赖性非同源末端连接和 PARP 抑制剂敏感性。
Nat Commun. 2018 Dec 17;9(1):5406. doi: 10.1038/s41467-018-07855-x.
2
Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.放射敏感性是 PARPi 耐药 BRCA1 缺陷型肿瘤获得的脆弱性。
Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.
3
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells.DYNLL1 与 MRE11 结合以限制 BRCA1 缺陷细胞中的 DNA 末端切除。
Nature. 2018 Nov;563(7732):522-526. doi: 10.1038/s41586-018-0670-5. Epub 2018 Oct 31.
4
Nuclear cGAS suppresses DNA repair and promotes tumorigenesis.核 cGAS 抑制 DNA 修复并促进肿瘤发生。
Nature. 2018 Nov;563(7729):131-136. doi: 10.1038/s41586-018-0629-6. Epub 2018 Oct 24.
5
53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ.53BP1 与 REV7-shieldin 复合物的合作是 DNA 结构特异性 NHEJ 的基础。
Nature. 2018 Aug;560(7716):122-127. doi: 10.1038/s41586-018-0362-1. Epub 2018 Jul 25.
6
53BP1-RIF1-shieldin counteracts DSB resection through CST- and Polα-dependent fill-in.53BP1-RIF1-shieldin 通过 CST 和 Polα 依赖性填补来阻止 DSB 切除。
Nature. 2018 Aug;560(7716):112-116. doi: 10.1038/s41586-018-0324-7. Epub 2018 Jul 18.
7
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.Shieldin 复合物促进 DNA 末端连接，并在 BRCA1 缺失细胞中对抗同源重组。
Nat Cell Biol. 2018 Aug;20(8):954-965. doi: 10.1038/s41556-018-0140-1. Epub 2018 Jul 18.
8
The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication.聚（ADP-核糖）聚合酶作为 DNA 复制过程中未连接的冈崎片段传感器的重要性。
Mol Cell. 2018 Jul 19;71(2):319-331.e3. doi: 10.1016/j.molcel.2018.06.004. Epub 2018 Jul 5.
9
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.选择性缺失 PARG 可恢复 PAR 化并拮抗 PARP 抑制剂介导的合成致死性。
Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008.
10
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.CST 复合物介导双链断裂的末端保护并增强 BRCA1 缺陷细胞中 PARP 抑制剂的敏感性。
Cell Rep. 2018 May 15;23(7):2107-2118. doi: 10.1016/j.celrep.2018.04.046.
Zotero 插件